TABLE 2.

Factors associated with increased risk of polypharmacy and PIMs.

Characteristics		Number of studies	Relative ratio, RR	95% CI	p
Polypharmacy
Age	≥ 75 vs. 65–74	2	1.09	0.86, 1.39	0.486
Gender		3	0.88	0.73, 1.04	0.137
Tumor type
	Adenocarcinoma vs. other	2	1.02	0.75, 1.37	0.92
PIMs
Gender		2	1.04	0.99, 1.10	0.124
Tumor type
	NSCLC vs. SCLC	2	1.04	0.96, 1.12	0.341
	SCLC vs. other	2	0.95	0.86,1.05	0.361
	NSCLC vs. other	2	0.98	0.91,1.05	0.536

NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer.